Skip to main content
Premium Trial:

Request an Annual Quote

DiagnoCure Laboratory Gets New York Permit

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DiagnoCure has received a Clinical Laboratory Permit from New York State regulators for its CLIA-approved and CAP-certified laboratory, the company announced today.

The permit from the New York State Department of Health allows DiagnoCure's lab in West Chester, Penn., to use the company's Previstage GCC Colorectal Staging Test on commercial samples originating in New York, which could crack open a significant market for the test, DiagnoCure said in a statement.

Citing the American Cancer Society, the company said that New York has the third-highest rate of new colorectal cancer cases among states in the US.

"This license, coupled with the rollout of our colorectal cancer disease management program, is a considerable milestone in bringing our proprietary Previstage GCC test to colorectal specialists nationwide," said Valerie Palmieri, president of DiagnoCure Oncology Laboratories, in the company's statement.

She added the test is the only molecular test available to help better identify whether colorectal cancer has spread to the lymph nodes. The test received CLIA certification in 2008. In New York State, however, a CLIA-approved test must also receive clearance from state regulators for use.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.